• Mashup Score: 0
    Milvexian appears safe for secondary prevention of stroke - 2 year(s) ago

    In the AXIOMETIC-SSP trial, milvexian, a novel factor XIa inhibitor, was protective against ischemic stroke with no increased risk for intracranial hemorrhage compared with placebo in patients requiring secondary prevention.“Milvexian … has the potential to reduce stroke without an increase in intracranial hemorrhage,” Mukul Sharma, MD, MSc, deputy director of clinical affairs and

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CardiologyToday
      CardiologyToday

      In the AXIOMETIC-SSP trial, #milvexian was protective against ischemic #stroke with no increased risk for intracranial hemorrhage compared with placebo in patients requiring secondary prevention @uOttawa #ESCCongress @ESCardioNews #CardioTwitter https://t.co/FMYHXCJ3d9